Jane Street’s Aligos Therapeutics ALGS Stock Holding History

Jane Street’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,293	Closed	-$226K	–	11462
2025 Q4	$226K	Buy	+24,293	New	+$229K	﹤0.01%	9471
2024 Q3	–	Sell	-547	Closed	-$4.78K	–	9507
2024 Q2	$4.78K	Buy	+547	New	+$9.62K	﹤0.01%	9167
2023 Q2	–	Sell	-1,050	Closed	-$22.9K	–	8605
2023 Q1	$22.9K	Buy	1,050 +393	+60%	+$15K	﹤0.01%	8614
2022 Q4	$15.6K	Buy	+657	New	+$16.6K	﹤0.01%	8661

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jane Street's ALGS Position: Q1 2026 in Review

Jane Street sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 24,293 shares — an estimated $226K sold.

Jane Street first reported a position in ALGS in Q4 2022 and held it in 4 quarters. The position peaked at $226K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Jane Street reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 24,293 Aligos Therapeutics shares in Q1 2026, an estimated $226K.
Jane Street first reported a position in Aligos Therapeutics in Q4 2022 and held it in 4 quarters.
Jane Street's Aligos Therapeutics position peaked at $226K in Q4 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.